Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, Yang Z, Sator-Schmitt M, Engel H, Li X, Broderick C, Jin G, Gomez-Eerland R, Rozeman L, Lei X, Matsuo H, Yang C, Hofland I, Peters D, Broeks A, Laport E, Fitz A, Zhao X, Mahmoud MAA, Ma X, Sander S, Liu HK, Cui G, Gan Y, Wu W, Xiao Y, Heck AJR, Guan W, Lowe SW, Horlings HM, Wang C, Brummelkamp TR, Blank CU, Schumacher TNM, Sun C. Miao B, et al. Among authors: peters d. Cancer Cell. 2023 Oct 9;41(10):1817-1828.e9. doi: 10.1016/j.ccell.2023.08.008. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683639 Free article.
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R. Majewski IJ, et al. Among authors: peters d. J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209. J Pathol. 2013. PMID: 23661334
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK. Sobral-Leite M, et al. Among authors: peters d. Oncoimmunology. 2018 Sep 11;7(12):e1509820. doi: 10.1080/2162402X.2018.1509820. eCollection 2018. Oncoimmunology. 2018. PMID: 30524905 Free PMC article.
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Among authors: peters d. Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Nat Med. 2019. PMID: 31086347 Clinical Trial.
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL, Elshof LE, Van de Vijver K, Groen EJ, Almekinders MM, Sanders J, Bierman C, Peters D, Hofland I, Broeks A, van Leeuwen FE, Rutgers EJT, Schmidt MK, Schaapveld M, Lips EH, Wesseling J. Visser LL, et al. Among authors: peters d. Am J Surg Pathol. 2019 Nov;43(11):1574-1582. doi: 10.1097/PAS.0000000000001306. Am J Surg Pathol. 2019. PMID: 31206365
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Among authors: peters d. Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5. Nat Med. 2019. PMID: 31209337
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, van der Poel HG, Bruining A, Lubeck Y, Sikorska K, Boellaard TN, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, van den Broek M, Wessels LFA, Blank CU, van Rhijn BW, van der Heijden MS. van Dijk N, et al. Among authors: peters d. Nat Med. 2020 Dec;26(12):1839-1844. doi: 10.1038/s41591-020-1085-z. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046870 Clinical Trial.
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N, Gil-Jimenez A, Silina K, van Montfoort ML, Einerhand S, Jonkman L, Voskuilen CS, Peters D, Sanders J, Lubeck Y, Broeks A, Hooijberg E, Vis DJ, van den Broek M, Wessels LFA, van Rhijn BWG, van der Heijden MS. van Dijk N, et al. Among authors: peters d. Front Immunol. 2021 Dec 20;12:793964. doi: 10.3389/fimmu.2021.793964. eCollection 2021. Front Immunol. 2021. PMID: 34987518 Free PMC article. Clinical Trial.
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, van den Heuvel MM, Broeks A, Haanen JBAG, Schumacher TN, Meijer GA, Smit EF, Monkhorst K, Thommen DS. Hummelink K, et al. Among authors: peters d. Clin Cancer Res. 2022 Nov 14;28(22):4893-4906. doi: 10.1158/1078-0432.CCR-22-0992. Clin Cancer Res. 2022. PMID: 35852792 Free PMC article.
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
Gil-Jimenez A, van Dijk N, Vos JL, Lubeck Y, van Montfoort ML, Peters D, Hooijberg E, Broeks A, Zuur CL, van Rhijn BWG, Vis DJ, van der Heijden MS, Wessels LFA. Gil-Jimenez A, et al. Among authors: peters d. Nat Commun. 2024 Mar 21;15(1):2538. doi: 10.1038/s41467-024-46450-1. Nat Commun. 2024. PMID: 38514623 Free PMC article.
1,921 results